Rapamycin Inhibits IGF-1 Stimulated Cell Motility through PP2A Pathway by Liu, Lei et al.
Rapamycin Inhibits IGF-1 Stimulated Cell Motility
through PP2A Pathway
Lei Liu
1, Long Chen
1, Yan Luo
1, Wenxing Chen
1, Hongyu Zhou
1, Baoshan Xu
1, Xiuzhen Han
1, Tao Shen
1,
Shile Huang
1,2*
1Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States of America, 2Feist-Weiller
Cancer Center, Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States of America
Abstract
Serine/threonine (Ser/Thr) protein phosphatase 2A (PP2A) has been implicated as a novel component of the mammalian
target of rapamycin (mTOR) signaling pathway. Recently we have demonstrated that mTOR regulates cell motility in part
through p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1) pathways. Little is
known about the role of PP2A in the mTOR-mediated cell motility. Here we show that rapamycin inhibited the basal or
insulin-like growth factor 1 (IGF-1)-induced motility of human Ewing sarcoma (Rh1) and rhabdomyosarcoma (Rh30) cells.
Treatment of the cells with rapamycin activated PP2A activity, and concurrently inhibited IGF-1 stimulated phosphorylation
of Erk1/2. Inhibition of Erk1/2 with PD98059 did not significantly affect the basal mobility of the cells, but dramatically
inhibited IGF-1-induced cell motility. Furthermore, inhibition of PP2A with okadaic acid significantly attenuated the
inhibitory effect of rapamycin on IGF-1-stimulated phosphorylation of Erk1/2 as well as cell motility. Consistently, expression
of dominant negative PP2A conferred resistance to IGF-1-stimulated phosphorylation of Erk1/2 and cell motility. Expression
of constitutively active MKK1 also attenuated rapamycin inhibition of IGF-1-stimulated phosphorylation of Erk1/2 and cell
motility. The results suggest that rapamycin inhibits cell motility, in part by targeting PP2A-Erk1/2 pathway.
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Introduction
The mammalian target of rapamycin (mTOR), a member of the
phosphoinositide-39 kinase-related kinase family, is a central
controller of cell proliferation, growth and survival [1]. Rapamycin
can form a complex with FK506 binding protein 12 (FKBP-12)
and then bind mTOR, selectively inhibiting its kinase activity and
function [1]. Recently, two mTOR complexes (mTORC1 and
mTORC2) have been identified in mammalian cells [1].
mTORC1 is composed of mTOR, mLST8 (also termed G-
protein b-subunit-like protein, GbL, a yeast homolog of LST8),
PRAS40 (proline-rich Akt substrate 40 kDa) and raptor (regula-
tory-associated protein of mTOR), and is rapamycin-sensitive [2–
8]. In response to growth factors and nutrients, mTORC1
regulates cell proliferation and growth by modulating many
processes, including protein synthesis and ribosome biogenesis
through downstream effectors like 4E-BP1 (eukaryotic initiation
factor 4E binding protein 1) and S6K1 (ribosomal p70 S6 kinase 1)
[1]. mTORC2 consists of mTOR, mLST8, mSin1 (mammalian
stress-activated protein kinase-interacting protein 1), rictor (rapa-
mycin insensitive companion of mTOR), and PRR5 (proline-rich
protein 5), and is rapamycin-insensitive [9–15]. mTORC2
phosphorylates Akt [12,14,16], and controls cytoskeleton organi-
zation and cell survival [10,11]. Most recently, mTORC2 has
been reported to phosphorylate SGK1 (serum and glucocorticoid-
inducible kinase 1) [17], although this remains controversial [18].
Both mTORC1 and mTORC2 interact with a negative regulator
DEPTOR [19].
Clinical trials have demonstrated that rapamycin and its analogs
(CCI-779, RAD001 and AP23573) (termed rapalogs) are prom-
ising anticancer drugs. They share same mechanism and
specifically block the function of mTOR, inhibiting growth of
numerous solid tumors (renal, breast, prostate, colon and brain
cancers) with only mild side effects [20]. Intensive studies have
focused on the crucial roles of mTOR in controlling cell
proliferation, growth and survival. Recently this laboratory and
others have further revealed its pivotal role in regulating cell
migration [21–26]. We found that rapamycin suppresses IGF-1
stimulated F-actin reorganization and migration in various tumor
cell lines by inhibiting mTORC1-mediated 4E-BP1 and S6K1
pathways [23]. This is in part associated with rapamycin inhibition
of phosphorylation of the focal adhesion proteins (FAK, paxillin
and p130
Cas) [24].
PP2A, a serine/threonine (Ser/Thr) protein phosphatase, is a
heterotrimeric holoenzyme composed of a catalytic subunit
(PP2Ac), an A subunit (also termed PR65), and members of the
B subunit families, such as B (PR55), B9 (PR61), B0 (PR72), and
B90 (PR93/PR110) [27]. The phosphatase activity of PP2Ac is
modulated by its association with PP2A-A, and -B regulatory
subunits [27]. Of interest, PP2A has been identified as the
phosphatase responsible for the dephosphorylation of S6K1 and
4E-BP1, and inhibition of mTOR with rapamycin has been shown
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10578to stimulate these PP2A-mediated events [28], suggesting that
PP2A is a novel downstream target of mTOR. It has been
suggested that a4 protein, the mammalian homolog of yeast
Tap42 [29], associates with PP2Ac [30]. Association of a4 with
PP2A, PP4, and PP6 has been linked to rapamycin sensitivity
[30–32]. In yeast TOR phosphorylates Tap42 and promotes its
association with Pph21/22 and Sit4 (encoding PP2Ac and PP6,
respectively), inhibiting their activities [29,33], although there
exists disputation [34,35]. As in yeast, the consequence of a4
dissociation from PP2A or PP6 in mammalian cells is contradic-
tory. For instance, rapamycin has been reported to inhibit cell
proliferation by decreasing PP2A activity through dissociation a4
from the PP2Ac [36]. However, other studies [31,34] do not
demonstrate rapamycin-induced dissociation of a4 from PP2A
or PP6.
PP2A negatively regulates Erk1/2 [37,38], though this notion is
controversial [39]. Activation of Erk1/2 by IGF-1 is associated
with mitogenesis and cell motility [40]. Inhibition of PP2A activity
promotes motility in a number of transformed cells and cancer cell
lines [41], whereas activation of PP2A by b2-adrenergic receptor
agonists inhibits motility of keratinocytes [38]. Because PP2A is
negatively regulated by mTOR, we hypothesized that mTOR may
regulate cell motility in part through PP2A-Erk1/2 pathway. This
study was designed to test the hypothesis.
Materials and Methods
Cell culture
Human rhabdomyosarcoma Rh30 and Ewing sarcoma Rh1
(gifts from Dr. Peter J. Houghton, St Jude Children’s Research
Hospital, Memphis, TN, USA) were grown in antibiotic-free
RPMI 1640 medium (Mediatech, Herndon, VA, USA) supple-
mented with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT,
USA) at 37uC and 5% CO2. Human embryonic kidney (HEK)
293 (American Type Culture Collection, Manassas, VA), 293TD
and 293A cells (Invitrogen, Carlsbad, CA, USA) were grown in
antibiotic-free Dulbecco’s modified Eagle medium (DMEM)
(Mediatech) supplemented with 10% heat-inactivated FBS and
non-essential amino acid (Mediatech) at 37uC and 5% CO2. For
experiments where cells were deprived of serum, cell monolayers
were washed with phosphate buffered saline (PBS), and incubated
in the serum-free DMEM. Rh1 and Rh30 clones [42] stably
expressing empty vector pcDNA3 and AU1-tagged rapamycin-
resistant mutant mTOR (S2035I), mTORrr, were generously
provided by Dr. Peter J. Houghton (St. Jude Children’s Research
Hospital, Memphis, TN). Rh1 and Rh30 clones stably expressing
hemagglutinin (HA)-tagged dominant-negative (dn) protein phos-
phatase 2A catalytic subunit (PP2Ac) (L199P) (dn-PP2A) were
described previously [43]. The above clones were expanded in
growth medium containing 500 mg/ml G418 for further experi-
ments. Individual clones expressing mTORrr and dn-PP2A were
examined by Western blotting with antibodies to AU1 and HA,
respectively. The functions of the mutant proteins in the cells were
further confirmed by detection of phosphorylation of S6K1 and
4E-BP1 (for mTORrr) and Erk1/2 (for dn-PPP2A), as described
[42,43].
Recombinant adenoviral constructs and infection of cells
The recombinant adenovirus expressing the green fluorescence
protein (GFP) (Ad-GFP) was described previously [23]. To
construct recombinant adenoviruses expressing FLAG-tagged
constitutively active and dominant negative MKK1, DNA
fragments encoding the corresponding mutants were excised from
pMCL-MKK1-R4F and pMCL-MKK1-K97M [44] (gifts from
Dr. Natalie Ahn, University of Colorado, Boulder, CO, USA), and
then sub-cloned to FLAG-tagged pENTR11 shuttle vector. The
recombinant adenovirus was generated using ViraPower
TM
Adenoviral Gateway
TM Expression Kit (Invitrogen, Carlsbad,
CA, USA) following the manufacture’s instruction. All adenovi-
ruses were amplified, titrated and used as described [23,24].
Lentiviral shRNA cloning, production, and infection
Lentiviral shRNAs to mTOR and GFP were described
previously [24]. For use, monolayer cells, when grown to about
70% confluence, were infected with above lentiviral shRNAs in
the presence of 8 mg/ml polybrene for 12 h twice at an interval of
6 h. Uninfected cells were eliminated by exposure to 2 mg/ml
puromycin for 48 h before use.
Western blot analysis
Western blotting was performed as described previously [23].
The primary antibodies used included antibodies to FLAG, b-
tubulin (Sigma, St. Louis, MO, USA), HA, Erk2, MKK1, mTOR
(FRAP), p-S6K1 (Thr389), S6K1 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), and p-Erk1/2 (Thr202/Tyr204) (Cell
Signaling, Beverly, MA, USA).
In vitro PP2A phosphatase assay
Cells were lysed in 50 mM Tris-HCl buffer, pH 7.0, containing
1% Nonidet P-40, 2 mM EDTA, and protease inhibitor cocktail
(Sigma, 1:1000). PP2Ac was immunoprecipitated with antibodies
to PP2Ac (Millipore, Temecula, CA, USA), and protein A/G-
agarose (Santa Cruz Biotechnology). Subsequently, the beads were
washed three times with the above lysis buffer, and twice with the
phosphatase assay buffer (50 mM Tris-HCl, pH 7.0, 0.1 mM
CaCl2). The phosphatase activity of immunoprecipitated PP2A
was assayed with a Ser/Thr Phosphatase Assay kit 1 using
KRpTIRR as the substrate peptide (Millipore) following the
manufacturer’s instructions. Absorbance was measured at 595 nm
using a Wallac 1420 Multilabel Counter (PerkinElmer Life
Sciences, Wellesley, MA, USA). Because the optical density
(OD) values varied from experiment to experiment, PP2A activity
was calculated using the fold change (arbitrary units) in each
experiment. Finally all data (from different batches of experiments)
were pooled for statistical analysis.
Cell motility assay
Cell motility was determined using the wound healing assay, as
described previously [23].
Statistical analysis
Results were expressed as mean values 6 standard error (mean 6
SE). The data were analyzed by one-way analysis of variance
(ANOVA) followed by post-hoc Dunnett’s t-test for multiple
comparisons. A level of P,0.05 was considered to be significant.
Results
Rapamycin activates protein phosphatase 2A in an
mTOR-dependent manner
Our previous studies have shown that rapamycin suppresses
IGF-1 stimulated motility in various tumor cell lines in part by
inhibiting mTORC1-mediated 4E-BP1 and S6K1 pathways [23].
Since PP2A, a negative regulator of cell motility [41], has been
implicated as a novel downstream target of mTOR [28], we
determined whether rapamycin inhibits cell motility by activating
PP2A. We found that under serum-free conditions, exposure to
Role of PP2A in Cell Motility
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phosphatase activity of PP2A in Rh30 cells (Fig. 1A). The
rapamycin-induced activation of PP2A was sustained for at least
24 h (Fig. 1A). Furthermore, we found that IGF-1 decreased the
activity of PP2A, which was prevented by rapamycin (Fig. 1B). As
expected, okadaic acid (OA), an inhibitor of PP2A, inhibited the
basal PP2A activity by ,90%, and also completely blocked
rapamycin-induced PP2A activity (Fig. 1B).
To understand whether rapamycin activates PP2A through
inhibition of mTOR, Rh1 and Rh30 cells stably expressing a
rapamycin-resistant mutant mTOR (S2035I), mTORrr, that
prevents binding of FKBP-rapamycin but has intact kinase
activity, were used. We found that expression of mTORrr did
not significantly reduce the basal PP2A activity, but conferred high
resistance to rapamycin inhibition of PP2A activity in Rh30 cells
(Fig. 1C). Similar data were observed in Rh1/mTORrr cells (data
not shown), indicating that rapamycin-induced activation of PP2A
is mTOR-dependent. This is further supported by our findings
that downregulation of mTOR by ,85% with lentiviral shRNA
increased the PP2A activity by approximately 1.8 fold, mimicking
the effect of rapamycin on PP2A (Fig. 1D). Our results support the
notion that PP2A lies downstream of mTOR and is negatively
regulated by mTOR.
Rapamycin suppresses IGF-1 stimulated phosphorylation
of Erk1/2 in an mTOR-dependent manner
Since Erk1/2, negatively regulated by PP2A [37,38], have been
implicated in the regulation of cell motility [39], we next
investigated whether the inhibitory effect of rapamycin on cell
motility is through downregulation of Erk1/2. We found that
treatment of cells with IGF-1 (10 ng/ml) or rapamycin (100 ng/
ml) for ,2 h did not significantly alter the protein levels of Erk1/2
(Fig. 2A). However, IGF-1 induced robust activation of Erk1/2, as
detected by Western blotting with an antibody that recognizes
phospho-Erk1/2 (Thr202/Tyr204). Activation of Erk1/2 was
rapid but transient. Phosphorylation was maximal after 5 min of
IGF-1 stimulation, and then declined. Of interest is that IGF-1-
induced activation of Erk1/2 was dramatically blocked by
rapamycin, at concentrations of 10–1,000 ng/ml, in parental
Rh1 (Fig. 2A) or Rh30 cells (data not shown).
To unveil whether rapamycin inhibits phosphorylation of Erk1/
2 through inhibition of mTOR, Rh1 and Rh30 cells stably
expressing mTORrr were used. As shown in Fig. 2B and 2C,
expression of mTORrr did not obviously alter the basal or IGF-1-
induced phosphorylation of Erk1/2, but conferred high resistance
to rapamycin inhibition of IGF-1-induced phosphorylation of
Erk1/2 in Rh1 and Rh30 cells, suggesting an mTOR-dependent
Figure 1. Rapamycin activates PP2A in an mTOR-dependent manner. Serum-starved Rh30 cells were exposed to rapamycin (Rapa, 100 ng/
ml) for the indicated time (A), or pretreated with or without rapamycin (Rapa, 100 ng/ml) or okadaic acid (OA, 100 nM) for 2 h, and then stimulated
with or without IGF-1 (10 ng/ml) for 1 h (B), or the indicated serum-starved Rh30 cells were exposed to rapamycin (Rapa, 100 ng/ml) for 2 h (C, D).
PP2A in cell lysates was immunoprecipitated with antibodies to PP2A catalytic subunit (PP2Ac) plus protein A/G agarose beads, followed by in vitro
phosphatase assay using Ser/Thr Phosphatase Assay Kit 1 (Millipore). Data represent mean 6 SE from 3–4 independent experiments.
aP,0.05 vs.
controls,
bP,0.05 vs. Rapa group.
doi:10.1371/journal.pone.0010578.g001
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RNA interference studies. Consistent with our previous findings
[24], lentiviral shRNA to mTOR silenced expression of mTOR
protein by ,85% in Rh30 cells, comparing with the control
shRNA (to GFP). Downregulation of mTOR, mimicking the effect
of rapamycin, dramatically decreased the mTOR kinase activity,
since the IGF-1-stimulated phosphorylation of S6K1 (T389),
routinely used as an indicator of mTOR kinase activity [1], was
not detectable by Western blotting (Left panel, Fig. 2D). As
expected, knockdown of mTOR, but not GFP, abrogated IGF-1-
induced phosphorylation of Erk1/2 in Rh1 cells (Right panel,
Fig. 2D). Similar results were also observed in mTOR-downreg-
ulated Rh30 cells (data not shown).
Inhibition of PP2A with okadaic acid confers resistance to
rapamycin inhibition of IGF-1-induced phosphorylation
of Erk1/2 and cell motility
It has been described that insulin or IGF-1 stimulates activation
of S6K1, which is attributed to mTOR repression of PP2A activity
against S6K1 [28]. To determine whether a similar mechanism
could explain rapamycin inhibition of IGF-1 activation of Erk1/2,
we used okadaic acid (OA), a relatively specific PP2A inhibitor
[45]. Because okadaic acid selectively inhibits PP2A without
inhibiting PP1 in intact cells at concentrations up to 100 nM [45],
serum-starved Rh1 cells were treated with rapamycin (100 ng/ml)
in the presence of OA (100 nM). As shown in Fig. 3A, IGF-1
(10 ng/ml, 5 min) stimulated Erk1/2 phosphorylation, and this
effect was inhibited by pretreatment with rapamycin (100 ng/ml,
2 h). Pretreatment with OA for 1 h reversed the inhibitory effect
of rapamycin on IGF-1-induced phosphorylation of Erk1/2. OA
also slightly increased the basal level of phosphorylation of Erk1/2
in the absence or presence of rapamycin (Fig. 3A). Similar results
were obtained with calyculin A, another PP2A inhibitor (data not
shown). These results support the findings that a cross-talk occurs
between mTOR and MAP kinases pathways [46]. IGF-1
stimulation of mTOR represses PP2A, resulting in activation of
Erk1/2 and this is prevented by rapamycin.
Next, we investigated the role of PP2A in mTOR-mediated cell
motility. To this end, a monolayer of Rh1 or Rh30 cells were
grown in 6-well plates to 80% confluence, and serum-starved in
DMEM for 24 h. Cell motility was assessed by the wound healing
assay, as described previously [23]. Following wounding, cells were
pretreated with or without OA (100 nM) for 1 h, then treated with
or without rapamycin (100 ng/ml) for 2 h, followed by stimulation
with or without IGF-1 (10 ng/ml) for 22 h. Consistent with our
previous findings [23,24], rapamycin inhibited the basal or IGF-1-
stimulated cell motility by 60–70% in Rh1 cells (Fig. 3B). IGF-1
stimulated the cell motility by ,3-fold, and this was dramatically
attenuated by rapamycin to the basal level (Fig. 3B). OA alone did
not affect the basal or IGF-1 stimulated cell motility significantly,
but conferred high resistance to rapamycin inhibition of the basal
or IGF-1-stimulated cell motility in Rh1 cells (Fig. 3B). Similar
results were also observed in Rh30 cells (data not shown).
Expression of dominant negative PP2A confers resistance
to rapamycin inhibition of cell motility
To further determine the role of PP2A in the regulation of
Erk1/2 activity and cell motility, Rh1 and Rh30 cells were
Figure 2. Rapamycin suppresses IGF-1 stimulated phosphorylation of Erk1/2 in an mTOR-dependent manner. (A) Serum starved Rh1
cells were pretreated with or without rapamycin (Rapa, 100 ng/ml) for 2 h, and then stimulated with IGF-1 (10 ng/ml) for the indicated time. (B)
Serum-starved Rh1/pcDNA and Rh1/mTORrr cells were exposed to increasing concentrations of rapamycin (Rapa, 0–1000 ng/ml) for 2 h, and then to
IGF-1 for 15 min. (C) Serum-starved Rh30/pcDNA and Rh30/mTORrr cells were pretreated with or without rapamycin (Rapa, 100 ng/ml) for 2 h, and
then stimulated with or without IGF-1 (10 ng/ml) for 15 min. (D) Serum-starved Rh1 cells, infected with lentiviral shRNA to GFP (control) or mTOR,
were stimulated with IGF-1 (10 ng/ml) for 1 h (Left panel), or exposed to increasing concentrations of rapamycin (Rapa, 0–1000 ng/ml) for 2 h, and
then to IGF-1 for 15 min. For (A–D), cell lysates were analyzed by Western blotting using indicated antibodies.
doi:10.1371/journal.pone.0010578.g002
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(L199P, dn-PP2A). Consistent with previous findings [47],
expression of dn-PP2A, but not an empty vector (pcDNA3),
reduced the phosphatase activity of PP2A by approximately 80%
in serum-starved Rh1 cells (Fig. 4A). Rapamycin was able to
activate PP2A in the control cells, but not in the cells expressing
dn-PP2A (Fig. 4A). When the cells were serum-starved for 24 h,
and then stimulated with or without IGF-1 (10 ng/ml) for 10 min,
a low basal level of phosphorylation of Erk1/2 (Thr202/Tyr204)
was observed in Rh1/pcDNA cells (control), whereas considerable
level of phospho-Erk1/2 could be detected in Rh1/dn-PP2A cells.
IGF-1 was able to stimulate phosphorylation of Erk1/2 in Rh1/
pcDNA and Rh1/dn-PP2A cells (Fig. 4B). Also, due to failure to
activate PP2A in the cells expressing dn-PP2A (Fig. 4A),
rapamycin did not obviously inhibit IGF-1-induced phospho-
Erk1/2 in Rh1/dn-PP2A cells either (data not shown). Similar
results were observed in Rh30/pcDNA and Rh30/dn-PP2A cells
(data not shown). Of interest, expression of dn-PP2A did not
significantly affect the basal cell motility, but conferred high
resistance to rapamycin inhibition of the basal or IGF-1 stimulated
cell motility (Fig. 4C). Furthermore, we also noticed that cells
expressing dn-PP2A remained sensitive to an Erk1/2 inhibitor,
PD98059 (Fig. 4C).
Inhibition of Erk1/2 blocks IGF-1-induced cell motility
To address whether activation of Erk1/2 by IGF-1 is
responsible for increased cell motility, cells were exposed to
PD98059 (a selective inhibitor of MKK1/2, upstream of Erk1/2)
alone, or in combination with rapamycin. We found that
PD98059 did not alter the basal level of Erk1/2 phosphorylation
(data not shown), but at concentrations of 1–50 mM, significantly
inhibited IGF-1-induced activation of Erk1/2 in Rh1 cells
(Fig. 5A). PD98059 (10 mM) alone did not significantly affect the
basal mobility of cells, but obviously inhibited IGF-1-induced cell
motility (Fig. 5B). However, in combination with rapamycin,
PD98059 did not show a significant additive or synergistic effect
on rapamycin inhibition of IGF-1-stimulated cell motility (Fig. 5B).
Similar results were obtained with U0126 (5 mM), another
MKK1/2 inhibitor (data not shown).
Expression of constitutively active MKK1 confers
resistance to rapamycin inhibition of cell motility
To further define the role of Erk1/2 in mTOR-mediated cell
motility, we generated recombinant adenoviruses Ad-MKK1-R4F
and Ad-MKK1-K97M, encoding FLAG-tagged constitutively
active and dominant negative MKK1, respectively. Infection of
Rh30 cells with Ad-MKK1-R4F and Ad-MKK1-K97M, but not
Ad-GFP (control virus), resulted in expression of high levels of
FLAG-tagged MKK1 mutants (Fig. 6A). Expression of MKK1-
R4F resulted in robust phosphorylation of Erk1/2 even without
stimulation with IGF-1, whereas expression of MKK1-K97M
blocked IGF-1-stimulated phosphorylation of Erk1/2 (Fig. 6A),
indicating that the MKK1 mutants function as expected. Of
interest, expression of MKK1-R4F, but not GFP or MKK1-
K97M, in Rh30 cells prevented rapamycin inhibition of IGF-1
stimulated phosphorylation of Erk1/2 (Fig. 6A). Expression of
MKK1-R4F slightly reduced the basal or IGF-1 stimulated cell
motility, but conferred high resistance to rapamycin inhibition of
the basal or IGF-1-induced cell motility (Fig. 6B). In contrast,
expression of MKK1-K97M in the cells significantly inhibited the
basal or IGF-1 stimulated cell motility (Fig. 6B).
Discussion
Recently we have demonstrated that rapamycin inhibits F-
action reorganization and cell motility by inhibition of mTOR-
mediated S6K1 and 4E-BP1/eIF4E pathways [23,24]. Since
PP2A, a negative regulator of Erk1/2 and cell motility [37–39],
has been implicated as a novel downstream target of mTOR [28],
this study was set out to determine the role of PP2A-Erk1/2
pathway in mTOR-mediated cell motility. Here we show that
treatment with rapamycin activated PP2A and concurrently
suppressed IGF-1 stimulated phosphorylation of Erk1/2 in human
Ewing sarcoma (Rh1) and rhabdomyosarcoma (Rh30) cells.
Inhibition of PP2A with OA, or expression of dominant negative
PP2A significantly attenuated the inhibitory effect of rapamycin on
IGF-1-stimulated phosphorylation of Erk1/2 as well as cell
motility. Furthermore, expression of constitutively active MKK1
Figure 3. Inhibition of PP2A with okadaic acid confers
resistance to rapamycin inhibition of IGF-1-induced phosphor-
ylation of Erk1/2 and cell motility. (A) Serum-starved Rh1 cells were
pretreated treated with or without OA (100 nM) for 1 h, and then
treated with or without rapamycin (Rapa, 100 ng/ml) for 2 h, followed
by stimulation with or without IGF-1 (10 ng/ml) for 15 min. Cell lysates
were analyzed by Western blotting using indicated antibodies. b-tubulin
served as loading control. (B) Motility of Rh1 cells was determined by
the wound healing assay, as described in Materials and Methods.
Following wounding, serum-starved Rh1 cells were pretreated treated
with or without OA (100 nM) for 1 h, and then treated with or without
rapamycin (Rapa, 100 ng/ml) for 2 h, followed by stimulation with or
without IGF-1 (10 ng/ml) for 22 h. Cells migrated over the denuded area
were observed and photographed with an Olympus inverted phase-
contrast microscope equipped with Quick Imaging system. The number
of cells migrating per millimeter of scratch was counted. Results are
means 6 SE of 3–4 independent experiments.
aP,0.05, difference vs.
control group;
bP,0.05, difference vs. IGF-1 group.
doi:10.1371/journal.pone.0010578.g003
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rapamycin inhibition of IGF-1-stimulated cell motility. The results
suggest that rapamycin inhibits cell motility, in part by targeting
PP2A-Erk1/2 pathway.
The phosphatase activity of PP2Ac is modulated by its
association with PP2A-A, -B regulatory subunits and a4 protein
[27]. Association of a4 with PP2A, PP4, and PP6 has been linked
to rapamycin sensitivity [30–32], but this is controversial [34]. In
particular, some cellular effects of rapamycin have been described
to be independent of mTOR kinase activity [48,49]. For instance,
rapamycin inhibits differentiation of C2C12 cells, which is
independent of mTOR kinase activity [48], despite of existence
of disputation [50]. This promoted us to determine whether
rapamycin activation of PP2A is through inhibition of mTOR
kinase activity. Here we demonstrated that rapamycin failed to
activate PP2A in the cells expressing rapamycin-resistant mTOR
(mTORrr), but not in control cells expressing the empty vector
(pcDNA3) (Fig. 1), suggesting that rapamycin activation of PP2A is
indeed through inhibiting mTOR activity. This is further
supported by the observations that 1) rapamycin inhibited IGF-1
stimulated phosphorylation of Erk1/2 in the control cells, but not
in the cells expressing mTORrr (Fig. 2B,C); 2) downregulation of
mTOR, mimicking the effect of rapamycin, activated PP2A
(Fig. 1D) and inhibited IGF-1 stimulated phosphorylation of Erk1/
2 (Fig. 2D). The present data are consistent with our previous
results that the kinase activity of mTOR is necessary for IGF-1
stimulated F-actin reorganization and cell motility [23,24].
We found that PD98059 (10 mM) alone did not significantly
affect the basal mobility of cells, but dramatically inhibited IGF-1-
induced cell motility (Fig. 5). However, when used in combination
with rapamycin, PD98059 did not show a significant additive or
synergistic effect on rapamycin inhibition of IGF-1-stimulated cell
motility (Fig. 5). By contrast, inhibition of PP2A with OA
(100 nM) or expression of dn-PP2A significantly attenuated the
inhibitory effect of rapamycin on IGF-1-stimulated cell motility
(Fig. 3, 4). However, we also noticed that PD98059 was able to
block IGF-1 stimulated motility of the cells expressing dn-PP2A
(Fig. 4C). The data imply that PD98059 and rapamycin may
redundantly inhibit Erk1/2. PD98059 inhibits Erk1/2 by directly
inhibiting MEK1/2, whereas rapamycin inactivates Erk1/2 by
Figure 4. Expression of dominant negative PP2A confers resistance to rapamycin inhibition of cell motility. (A) Rh1 cells were stably
transfected with vector alone (Rh1/pcDNA) or with a vector expressing HA-tagged dn-PP2Ac (L199P), serum-starved for 24 h, and then treated with
or without rapamycin (Rapa, 100 ng/ml), followed by in vitro phosphatase assay using Ser/Thr Phosphatase Assay Kit 1 (Millipore). Data represent
mean 6 SE from 3–4 independent experiments.
aP,0.05 vs. Rh1/pcDNA control,
bP,0.05 vs. Rh1/pcDNA Rapa group. (B) Serum-starved Rh1/pcDNA
and Rh1/dn-PP2A cells were stimulated with or without IGF-1 (10 ng/ml) for 15 min, followed by Western blotting using the indicated antibodies. (C)
Motility of Rh1/pcDNA and Rh1/dn-PP2A cells was determined by the wound healing assay, as described in Materials and Methods. Serum-starved
cells were pretreated with or without rapamycin (Rapa, 100 ng/ml) or PD98059 (PD, 10 mM) for 2 h, and then stimulated with or without IGF-1 (10 ng/
ml) for 22 h. Results are means 6 SE of 3–4 independent experiments.
aP,0.05, difference vs. control group;
bP,0.05, difference vs. IGF-1 group.
doi:10.1371/journal.pone.0010578.g004
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addition, the results also indicate that the basal and the IGF-1-
induced motility of cells may be regulated through different
mechanisms. Though the basal or IGF-1-induced cell motility is
sensitive to rapamycin, only the latter appears to be Erk1/2-
dependent. Possibly, the basal motility of cells is associated with
considerable activation of S6K1 and/or phosphorylation of 4E-
BP1 [23]. It appears that mTOR-mediated cell motility requires a
coordination of multiple signaling molecules, at least including
Erk1/2, S6K1 and 4E-BP1. Our data suggest that full phosphor-
ylation of Erk1/2, S6K1 and 4E-BP1 is essential for a maximal cell
motility.
Here we show that rapamycin inhibited IGF-1 stimulated
phosphorylation of Erk1/2, which is related to activation of PP2A.
This is consistent with recent findings that rapamycin inhibited
IGF-1 or EGF stimulated phosphorylation of Erk1/2, not through
inhibiting the upstream kinase, as rapamycin did not inhibit
growth factor-induced phosphorylation of MKK1 (Ser217/221)
[46]. Instead, both IGF-1 and EGF caused dissociation of PP2Ac
from Erk1/2, which was partially prevented by rapamycin [46].
Downregulation of raptor inhibits IGF-1 stimulated phosphoryla-
tion of Erk1/2 [46] suggests that mTORC1 participates in the
regulation of PP2A-Erk1/2 pathway.
It has been described that IGF-1 activates Erk1/2 by
dissociating from Shc from PP2Ac [51]. To determine whether
mTORC1 regulates PP2A-Erk1/2 interaction by affecting the
association of PP2Ac with Shc, serum-starved Rh1 or Rh30 cells
were pretreated with or without rapamycin (100 ng/ml) for 2 h,
and then stimulated with or without IGF-1 (10 ng/ml) for 15 min,
followed by co-immunoprecipitation (with antibodies to either Shc
or PP2Ac). We found that neither IGF-1 (10 ng/ml, 15 min) nor
rapamycin (100 ng/ml, 2 h) affected the association of PP2Ac with
Shc in the cells (data not shown). The results are, to some extent,
in contrast to the previous findings in HIRc B cells (Rat-1
fibroblasts overexpressing human insulin receptors), in which
PP2Ac associated with Shc at the basal state and dissociated from
it in response to IGF-1 stimulation [51]. This is probably due to
Figure 5. Inhibition of Erk1/2 with PD98059 blocks IGF-1-
stimulated cell motility. (A) Serum-starved Rh1 cells were exposed to
increasing concentrations of PD98059 (0–50 mM) for 2 h, and then to
IGF-1 for 15 min, followed by Western blotting using the indicated
antibodies. (B) Motility of Rh1 cells was determined by the wound
healing assay. Serum-starved cells were pretreated for 2 h with
rapamycin (Rapa) (100 ng/ml) or PD98059 (PD) (10 mM) alone, or in
combination as indicated, followed by stimulation with or without IGF-1
(10 ng/ml) for 22 h. Results are means 6 SE of 3–4 independent
experiments.
aP,0.05, difference vs. control group;
bP,0.05, difference
vs. IGF-1 group.
doi:10.1371/journal.pone.0010578.g005
Figure 6. Expression of constitutively active MKK1 confers
resistance to rapamycin inhibition of cell motility. (A) Rh30 cells,
infected with Ad-MKK1-R4F, Ad-MKK1-K97M, and Ad-GFP (control),
respectively, were serum-starved for 24 h, pretreated with or without
rapamycin (Rapa, 100 ng/ml) for 2 h, and then stimulated with or
without IGF-1 (10 ng/ml) for 15 min, followed by Western blotting with
indicated antibodies. (B) Motility of Rh30 cells infected with Ad-MKK1-
R4F, Ad-MKK1-K97M or Ad-GFP was determined by the wound healing
assay. Results are means 6 SE of 3–4 independent experiments.
aP,0.05, difference vs. Ad-GFP control group;
bP,0.05, difference vs.
IGF-1 group.
doi:10.1371/journal.pone.0010578.g006
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Clearly, more studies are required to address the mechanism by
which mTORC1 regulates PP2A-Erk1/2 signaling.
In the studies, we also assessed the roles of other PP2A family
members, such as PP4, PP6 and PP5, in mTOR-mediated cell
motility, since these Ser/Thr protein phosphatses have been
reported as novel downstream molecules of mTOR as well [30–
36,53,54]. We found that downregulation of PP4 or PP6 neither
altered the basal or IGF-1 stimulated cell motility, nor affected
rapamycin inhibition of the cell motility in Rh1 and Rh30 cells.
However, downregulation of PP5 reduced the basal or IGF-1
stimulated cell motility by ,50%, and slightly enhanced
rapamycin inhibition of cell motility in Rh1 or Rh30 cells. The
data suggest that PP5 is a positive regulator for cell motility, and
PP4 and PP6 may not be involved in the regulation of cell motility.
It appeared that PP5 regulates cell motility in an Erk1/2-
independent manner, because downregulation of PP5 did not
obviously affect the basal or IGF-1 stimulated phosphorylation of
Erk1/2. How PP5 regulates cell motility is under investigation.
In summary, here we have shown that rapamycin inhibits IGF-1
stimulated cell motility by activating PP2A and concurrently
inhibiting phosphorylation of Erk1/2. Pharmacological or genetic
inhibition of PP2A attenuated the inhibitory effect of rapamycin
on IGF-1-stimulated phosphorylation of Erk1/2 as well as cell
motility, whereas expression of constitutively active MKK1 results
in robust phosphorylation of Erk1/2 and confers resistance to
rapamycin inhibition of IGF-1 stimulated cell motility. The results
suggest that rapamycin inhibits cell motility, in part by targeting
PP2A-Erk1/2 pathway.
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